Bisphosphonates in juvenile dermatomyositis with dystrophic calcinosis

References

• Rider LG, Lindley CB, Cassidy JT. Juvenile dermatomyositis. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of Pediatric Rheumatology. 6th ed. Philadelphia: Saunders Elsevier; 2011. pp. 375–413.
   Google Scholar
• Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371(9631):2201–12.
   PubMedGoogle Scholar
• Lowry CA, Pilkington CA. Juvenile dermatomyositis: extramuscular manifestations and their management. Curr Opin Rheumatol. 2009. 21(6):575–80.
   PubMedGoogle Scholar
• Weinel S, Callen JP. Calcinosis cutis complicating adult-onset dermatomyositis. Arch Dermatol. 2004;140(3):365–6.
   PubMedGoogle Scholar
• Blane CE, White SJ, Braunstein EM, Bowyer SL, Sullivan DB. Patterns of calcification in childhood dermatomyositis. Am J Roentgenol. 1984;142(2):397–400.
   PubMedGoogle Scholar
• Urganus AL, Zhao YD, Pachman LM. Juvenile dermatomyositis calcifications selectively displayed markers of bone formation. Arthritis Rheum. 2009;61(4):501–8.
   PubMedGoogle Scholar
• Nakamura H, Kawakami A, Ida H, Ejima E, Origuchi T, Eguchi K. Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis. J Rheumatol. 2006;33(8):1691–3.
   PubMedGoogle Scholar
• Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford). 2008;47(6):877–80.
   PubMedGoogle Scholar
• Fuchs D, Fruchter L, Fishel B, Holtzman M, Yaron M. Colchicine suppression of local inflammation due to calcinosis in dermatomyositis and progressive systemic sclerosis. Clin Rheumatol. 1986;5(4):527–30.
   PubMedGoogle Scholar
• Nakagawa T, Takaiwa T. Calcinosis cutis in juvenile dermatomyositis responsive to aluminum hydroxide treatment. J Dermatol. 1993; 20(9):558–660.
   PubMedGoogle Scholar
• Oliveri MB, Palermo R, Mautalen C, Hübscher O. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol. 1996;23(12):2152–5.
   PubMedGoogle Scholar
• Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr. 2001;138(5):763–6.
   PubMedGoogle Scholar
• Ambler GR, Chaitow J, Rogers M, McDonald DW, Ouvrier RA. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol. 2005;32(9):1837–9.
   PubMedGoogle Scholar
• Terroso G, Bernardes M, Aleixo A, Madureira P, Vieira R, Bernardo A, Costa L. Therapy of calcinosis universalis complicating adult dermatomyositis. Acta Reumatol Port. 2013;38(1):44–8.
   PubMedGoogle Scholar
• Martillotti J, Moote D, Zemel L. Improvement of calcinosis using pamidronate in a patient with juvenile dermatomyositis. Pediatr Radiol. 2014;44(1):115–8.
   PubMedGoogle Scholar
• Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A. Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine. 2009;77(1): 70–2.
   PubMedGoogle Scholar
• Marco Puche A, Calvo Penades I, Lopez Montesinos B. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol. 2010;28(1):135–40.
   PubMedGoogle Scholar
• Matsuoka Y, Miyajima S, Okada N. A case of calcinosis universalis successfully treated with low-dose warfarin. J Dermatol. 1998;25(11):716–20.
   PubMedGoogle Scholar
• Al-Mayouf SM, Alsonbul A, Alismail K. Localized calcinosis in juvenile dermatomyositis: successful treatment with intralesional corticosteroids injection. Int J Rheum Dis. 2010;13(3):e26–8.
   PubMedGoogle Scholar
• Peñate Y, Guillermo N, Melwani P, Martel R, Hernández-Machín B, Borrego L. Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin. J Am Acad Dermatol. 2009;60(6):1076–7.
   PubMedGoogle Scholar
• Schanz S, Ulmer A, Fierlbeck G. Response of dystrophic calcification to intravenous immunoglobulin. Arch Dermatol. 2008;144(5):585–7.
   PubMedGoogle Scholar
• Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011;38(7):1436–40.
   PubMedGoogle Scholar
• Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics. 2007;119 Suppl 2:S150–62.
   PubMed Web of Science ®Google Scholar
• Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(12 Suppl):2961–78.
   PubMedGoogle Scholar
• Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S118–57.
   PubMed Web of Science ®Google Scholar
• Frese E, Brown M, Norton B. Clinical reliability of manual muscle testing: middle trapezius and gluteus medius muscles. Phys Ther. 1987;67(7):1072–6.
   PubMedGoogle Scholar
• Boulman N, Slobodin G, Rozenbaum M, Rosner I. Calcinosis in rheumatic diseases. Semin Arthritis Rheum. 2005;34(6):805–12.
   PubMedGoogle Scholar
• Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr. 1983;103(6): 882–8.
   PubMedGoogle Scholar
• Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47(4):505–11.
   PubMedGoogle Scholar
• Pachman LM, Callen AM, Hayford J, Chung A, Sinacore J, Ramsey-Goldman R. Juvenile dermatomyositis: decreased calcinosis with intermittent high-dose intravenous methyl prednisolone therapy. Arthritis Rheum. 1994;37(Suppl):S429.
   Google Scholar
• Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge RC, Sundel RP. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum. 2009;60(6):1825–30.
   PubMedGoogle Scholar
• Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methyl prednisolone and methotrexate. Clin Rheumatol. 2000;19(2):138–41.
   PubMedGoogle Scholar
• Clynes R. IVIG therapy: interfering with interferon-gamma. Immunity. 2007;26(1):4–6.
   PubMedGoogle Scholar
• Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, et al. Fc gamma RIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immunoglobulin. Immunity. 2007;26(1):67–78.
   PubMedGoogle Scholar